Wedbush Predicts Lower Earnings for Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Analysts at Wedbush decreased their FY2026 earnings estimates for Kiniksa Pharmaceuticals in a research note issued to investors on Monday, January 13th. Wedbush analyst D. Nierengarten now forecasts that the company will earn $1.07 per share for the year, down from their previous estimate of $1.08. Wedbush has a “Outperform” rating and a $34.00 price objective on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ FY2027 earnings at $1.44 EPS.

Several other equities research analysts have also issued reports on KNSA. JPMorgan Chase & Co. lifted their price target on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Evercore ISI upped their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $36.60.

Kiniksa Pharmaceuticals Stock Performance

NASDAQ KNSA opened at $18.34 on Wednesday. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -130.99 and a beta of 0.29. Kiniksa Pharmaceuticals has a 52 week low of $16.56 and a 52 week high of $28.15. The stock’s 50 day moving average price is $20.94 and its two-hundred day moving average price is $23.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $112.21 million for the quarter, compared to the consensus estimate of $111.51 million. During the same quarter in the prior year, the firm posted ($0.20) earnings per share. The business’s revenue was up 67.4% on a year-over-year basis.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 8,969 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total transaction of $192,385.05. Following the completion of the sale, the chief financial officer now owns 22,958 shares of the company’s stock, valued at $492,449.10. This trade represents a 28.09 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 54.57% of the stock is currently owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of KNSA. Wellington Management Group LLP bought a new stake in shares of Kiniksa Pharmaceuticals during the third quarter worth approximately $1,192,000. Dimensional Fund Advisors LP grew its position in Kiniksa Pharmaceuticals by 31.2% during the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock worth $12,398,000 after buying an additional 157,741 shares in the last quarter. Segall Bryant & Hamill LLC bought a new position in shares of Kiniksa Pharmaceuticals in the third quarter worth $675,000. Parkman Healthcare Partners LLC lifted its holdings in shares of Kiniksa Pharmaceuticals by 16.7% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock worth $18,874,000 after acquiring an additional 108,102 shares during the period. Finally, Millennium Management LLC boosted its holdings in shares of Kiniksa Pharmaceuticals by 159.8% in the 2nd quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock valued at $11,612,000 after purchasing an additional 382,539 shares in the last quarter. Institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.